Aims to be a supportive ecosystem for early-stage biotech companies, providing a range of tailored services to help them navigate concept to commercialization.
100 subject matter experts were surveyed from smaller biotech innovators to gain insight into the dynamics and drivers of the current biologics market.
Will produce drug substance at its site in Halle, Germany, and complete clinical trial drug product production at its site in Amsterdam, the Netherlands.
Acquisition strengthens specialty medicines and respiratory pipeline with camlipixant, a highly selective P2X3 antagonist and potential best-in-class treatment for refractory chronic cough.
Collaboration will cover existing and future programs to aid in the development and commercialization of investigational medicines for hematologic malignancies.
The two parties plan to collaborate to introduce more high-quality innovative drugs into Southeast Asian markets to achieve joint and long-term development.